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Cardiovascular diseaseEukaryotic gene expression is tightly regulated transcriptionally and post-transcriptionally by a host of noncod-
ing (nc)RNAs. The best-studied class of short ncRNAs, microRNAs, mainly repress gene expression post-
transcriptionally. Long noncoding (lnc)RNAs, which comprise RNAs differing widely in length and function,
can regulate gene transcription as well as post-transcriptional mRNA fate. Collectively, ncRNAs affect a broad
range of age-related physiologic deteriorations and pathologies, including reduced cardiovascular vigor and
age-associated cardiovascular disease. This reviewpresents anupdate of our understanding of regulatory ncRNAs
contributing to cardiovascular health and disease as a function of advancing age. We will discuss (1) regulatory
ncRNAs that control aging-associated cardiovascular homeostasis and disease, (2) the concepts, approaches, and
methodologies needed to study regulatory ncRNAs in cardiovascular aging and (3) the challenges and opportunities
that age-associated regulatory ncRNAs present in cardiovascular physiology and pathology. This article is part of a
Special Issue entitled “CV Aging”.
© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
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1.1. Gene regulation by ncRNAs
The adaptation of mammalian cells to external and internal signals
requires precise transcriptional and post-transcriptional modulation of
gene expression patterns. Transcription is controlled mainly through
changes in chromatin composition and the recruitment of transcription
factors, while post-transcriptional control is elicited through pre-mRNA
splicing as well as mRNA transport, stability, storage, and translation.
Noncoding (nc)RNAs, the main focus of this review, inﬂuence all of
these gene regulatory levels [1]. Nuclear ncRNAs control transcription
by associating with chromatin and transcriptional activators and repres-
sors, and they control early post-transcriptional steps in gene regulation,
such as pre-mRNA splicing [2]. Cytoplasmic ncRNAs regulatemRNA turn-
over rate, mRNA storage and localization, andmRNA recruitment to ribo-
somes [3,4]. Since aberrant gene control underlies the age-related decline
in physiologic function and age-associated diseases, it is critically impor-
tant to understand how gene expression is altered in aging. Gene regula-
tion by DNA- and RNA-binding proteins affecting aging pathology and
physiology has been studied for decades. However, the deep and broad
impact of regulatory ncRNAs in aging is only now coming into view.
ncRNAs comprise a large and heterogeneous family. It includes
many RNAs that have been known for decades andmainly have house-
keeping functions, such as ribosomal RNAs (rRNAs), small nuclear RNAs
(snRNAs), small nucleolar RNAs (snoRNAs), and transfer RNAs (tRNAs).
However, the advent of tiling arrays and RNA-sequencing over the past
~15 years has revealed that large stretches of chromosomes previously
believed not to be transcribed, are actually transcribed and encode vast
numbers of ncRNAs [5]. Arbitrarily divided into long (lncRNAs,
N200 nt), and short (b200 nt) ncRNAs, these regulatory transcripts dis-
play distinct temporal and spatial expression patterns. As details of the
impact of ncRNAs on molecular and cellular processes are becoming
better understood, their roles in aging-associated physiologic processes
and disease conditions are also starting to emerge [6].
1.1.1. microRNAs
Although short RNAs also include piwi-interacting and small inter-
fering RNAs (piRNAs, siRNAs), microRNAs (miRNAs) have been most
actively studied in different contexts, including aging [7,8]. MicroRNAs
are single-stranded, ~22 nt-long ncRNAs that regulate gene expression
mainly by forming partial hybrids with target mRNAs and thereby
lowering their translation and/or stability [9]. AmicroRNA is transcribed
as a long, primary miRNA (pri-miRNA) which is cleaved by the micro-
processor complex (containing the ribonuclease Drosha) to generate
a miRNA precursor (pre-miRNA) that is exported to the cytoplasm
[4]. In the cytoplasm, the ribonuclease Dicer cleaves the pre-miRNA to
yield a ~22-bp-long duplex RNA; one strand of the duplex, the mature
miRNA, is loaded onto the RNA-induced silencing complex (RISC),
which contains Argonaute (Ago) proteins [10,11]. Each Ago-microRNA
complex targets a subset of mRNAs forming partial hybrids, often at
the 3′-untranslated region (UTR) of the mRNAs and frequently relying
on the miRNA ‘seed’ region (nucleotides 2–7). Several microRNAs
often work in concert to lower the expression of a shared target
mRNA. MicroRNAs have been implicated in virtually all areas of mam-
malian homeostatic gene regulation, and disruption of miRNA function
has been causally linked to a variety of cardiovascular diseases (CVDs)
that rise with advancing age [7,8,12,13].1.1.2. LncRNAs
LncRNAs can be classiﬁed according to their genomic localization
and biogenesis: lincRNAs are expressed from intergenic regions, anti-
sense lncRNAs are expressed from the opposite strand of mRNAs and
lncRNAs, pseudogene-encoded lncRNAs are transcribed from vestigial
genes that lost their coding potential, long intronic ncRNAs are present
in introns of annotated genes, promoter-associated lncRNAs are tran-
scribed from the promoter regions of coding mRNAs, and circular
RNAs are often generated by the splicing machinery [14].
This large class of ncRNAs can also be classiﬁed according to their
molecularmechanismof action. (1) Epigenetic regulation: somenuclear
lncRNAs regulate gene expression by serving as scaffolds, bridges, and
tethers of factors that regulate the state of the chromatin. By recruiting
chromatin-modiﬁcation enzymes, lncRNAs can transiently or perma-
nently activate/inactivate genes and chromosomal regions. The ability
to recognize DNA sequences uniquely enables lncRNAs to elicit highly
precise, sequence-speciﬁc actions on transcription. Examples of
chromatin-remodeling lncRNAs are XIST and HOTAIR [15,16]. (2) Tran-
scriptional regulation: lncRNAs can also assemble transcriptional activa-
tors and repressors tomodulate the rates of RNApolymerase II initiation
and elongation. Examples of transcription-modulatory lncRNAs include
NEAT1, ANRIL (CDKN2B-AS), GAS5, and MALAT1 [16,17]. (3) Nuclear
compartmentalization: some nuclear lncRNAs have been implicated in
maintaining nuclear structures, including nuclear speckles,
paraspeckles, and interchromatin granules; examples include
TUG1, MALAT1, NEAT1, and FIRRE [17]. (4) Post-transcriptional
gene regulation: lncRNAs that basepair with mRNAs can modulate
the translation and/or the stability of target mRNAs (e.g., 1/2-
sbsRNAs, LINCRNAP21 [18,19]) while lncRNAs that do not basepair
can affect precursor mRNA splicing and translation by acting as co-
factors or competitors of RNA-binding proteins [20,21]. (5) Com-
peting endogenous RNAs (ceRNAs): although lncRNAs are
generally low-abundance transcripts, some lncRNAs accumulate
because they are highly stable (e.g., circular RNAs) and can function
as decoys or sponges for microRNAs (e.g., LINCMD1 [22]) and possi-
bly other regulatory factors [23]. (6) Post-translational gene regu-
lation on protein turnover has also been reported for the lncRNA
HOTAIR, which scaffolds pairs of E3 ubiquitin ligases and their sub-
strates [24]. As reviewed comprehensively elsewhere [25,26],
lncRNA-modulated gene expression patterns are relevant to a
variety of cell functions with impact upon many age-associated
conditions.
1.2. Aging and CVDs
Age is the most important risk factor for CVDs, the most prominent
cause of death worldwide [http://www.who.int/cardiovascular_
diseases/resources/atlas/en/.]. Advancing age increases exposure to car-
diovascular risk factors, and elicits intrinsic cardiovascular changes that
compromise both the cardiovascular reserve capacity and the threshold
for primary diseases to manifest [27,28].
The aging heart is characterized by several detrimental changes such
as left ventricular hypertrophy, diastolic dysfunction, valve degenera-
tion, increased cardiacﬁbrosis, increased prevalence of atrialﬁbrillation,
and decreased maximal exercise capacity [29,30]. Endothelial function,
particularly endothelium-dependent dilation [31,32], also decreases
with aging; this decline is due, at least in part, to the reduced bioavail-
ability of nitric oxide (NO) following inﬂammation and oxidative stress
144 S. Greco et al. / Journal of Molecular and Cellular Cardiology 83 (2015) 142–155in the elderly [33,34]. Dysfunctional endothelium correlateswith higher
systolic and pulse pressure, and, consequently, with increased risk
of age-associated conditions such as atherosclerosis, hypertension,
acute myocardial infarction (AMI), and stroke [35]. Additionally, the
walls of the arteries and arterioles become thicker and less elastic,
making the vessels stiffer and less resilient [35,36].
2. Noncoding RNA in cardiovascular aging and age-associated CVDs
Our understanding of ncRNA function in the molecular mechanisms
underpinning the age-associated changes in the cardiovascular systems
ismuchmore advanced formiRNAs than for lncRNAs. Thus, a provision-
al but already delineated scenario is emerging, with speciﬁc miRNAs
regulating a variety of cardiovascular functions in both homeostasis
and disease. By contrast, for lncRNAs, in most circumstances, we have
just started scratching the surface, and, at the moment, the existing
data linking individual lncRNAs and age-associated CVDs are mainly
correlative. While many more studies speciﬁcally aimed at dissecting
ncRNA functions in cardiovascular system aging are needed, the ncRNAs
already identiﬁed in age-related CVDs are summarized in Table 1.
2.1. miRNAs
MiRNAs are involved in virtually all processes of physiology and dis-
ease, including aging [11,37,38]. Some 65 miRNAs have been identiﬁed
that display signiﬁcantly different expression levels between young
adult heart and older adult heart [39]. Here, we will review the miRNAs
related to the dysfunction of several well-recognized age-associated
processes affecting the cardiovascular system, including senescence,
nutrient sensing, oxidative stress response, inﬂammation, and silent
mating type information regulation 2 homolog (SIRT1)-regulated
events.
2.1.1. Senescence
Cells from normal animal tissue placed in culture divide for a ﬁnite
number of times but eventually stop proliferating and enter a state of
terminal growth arrest named senescence [40]. Replicative senescence
is triggered by the progressive shortening of the telomeres that results
from cell division and by exposure to a range of damaging condi-
tions [41]. Senescent cells do not divide, but they can remain viable
and metabolically active for a long time, displaying a large and ﬂat
morphology, cytoplasmic vacuoles, enhanced autophagy, and elevated
activity of lysosomal β-galactosidase [11,42]. Many senescent cells
also display a characteristic senescence-associated secretory phenotypeTable 1
ncRNAs and age-related cardiovascular diseases.
ncRNA Disease/condition Modulation Refs
miR-146 Heart failure Up [54]
miR-17-92 cluster Heart failure (mouse) Down [69]
miR-1 Heart failure, hypertrophy (mouse) Up [79]
miR-216a Heart failure Up [188]
miR-29 family Aorta aneurysm Up [53]
miR-155 Atherosclerotic lesions Up [59]
miR-21 Atherosclerotic plaques Up [96]
miR-216a Atherosclerotic plaques Up [103]
miR-217 Atherosclerotic plaques Up [109]
miR-1 Myocardial infarction (mouse) Up [132]
miR-34a Myocardial infarction (mouse) Up [61]
miR-200c Peripheral ischemia Up [90]
miR-210 Peripheral ischemia Up [99]
miR-145 Ischemia/reperfusion Down [97]
Mkk7 Heart failure (mouse) Down [126]
Mhrt Heart failure (mouse) Down [132]
H19 Heart failure Up [189]
Alc1-AS Hypertrophy (mouse) Up [190]
Chrf Hypertrophy (mouse) Down [125]
Mirt1/Mirt2 Myocardial infarction (mouse) Up [137](SASP) [43], whereby they secrete many cytokines and chemokines
(e.g., GM-CSF, IL-6, IL-8, IL-1α), and matrix metalloproteases
(e.g., MMP-1,MMP-3). Another hallmark of senescence is the activation
of tumor suppression pathways, mainly those controlled by p53/p21
and pRB/p16 [41]. Finally, since senescent cells frequently experience
oxidative and genotoxic damage, they generally express DNA-damage
response proteins, such as γ-H2AX, NIBRIN (NBS), MDC1, and 53BP1
[41].
Cellular senescence has been studied most extensively in cultured
cells, but there is broad recognition that senescence occurs in vivo and
affects aging phenotypes profoundly [41]. Since senescent cells accumu-
late in tissues as the organism ages, their metabolic behavior and their
signature gene expression proﬁle have been linked to a number of
age-related physiologic and pathologic changes including CVDs [44,
45]. For instance, accumulation of senescent endothelial cells (ECs)
in atherosclerotic lesions is an important factor contributing to age-
associated arterial dysfunction [46,47].
Several transcription factors, such as p53 and proteins in the AP-1,
E2F, Id and Ets families, have been implicated in driving senescence. In
addition, several RNA-binding proteins can regulate senescence via
post-transcriptional gene regulation, including human antigen R
(HuR), AU-binding factor 1 (AUF1), and tristetraprolin (TTP), through
their association with target mRNAs that encode senescence factors
[48,49]. However, a growing number of regulatory miRNAs also inﬂu-
ence senescence-associated gene expression patterns by regulating
key molecular pathways (Fig. 1):
• pRB/p16 pathway. Senescent cells have active (hypophosphorylated)
pRB, resulting from risen levels of two potent inhibitors of cyclin-
dependent kinases (cdks, which are pRB kinases): p21 (in part upreg-
ulated via p53) and p16. Some miRNAs that reduce p21 abundance
(e.g., miR-106b, miR-130b) decline during senescence [50,51].
• p53/p21 pathway. Senescent cells have elevated levels of p53, a pro-
tein subject to negative regulation by MCM5 (which is repressed
by miR-885-5p) [52]. Elevated p53 transcriptionally upregulates
miR-34a, which in turn reduces the levels of several proliferative
proteins (E2F, c-Myc, cyclins and cdks) and anti-apoptotic proteins
(Bcl-2 and SIRT1).
• Senescent cell-speciﬁc gene expression programs. Numerous proteins
modulate senescence-associated gene transcription, such as PCGF4,
HMGA2, RARγ and B-Myb (MYBL2), while other proteins affect
senescence-associated gene expression post-transcriptionally, includ-
ing the splicing factor ASF/SF2 and themRNA stability and translation
regulator HuR. Each of these proteins is also subject to control by
senescence-associated miRNAs [11], and some of these miRNAs
cross-talk with the p53/p21 and the p16/RB pathways (e.g., HMGA2
represses p21 transcription and Bmi-1 represses p16 transcription).
Importantly, senescence factors can also directly modulate the
expression of senescence-regulatory miRNAs; for example, pRB tran-
scriptionally increases miR-29/miR-30 levels and this regulation can
impact upon the deposition of extracellular matrix (ECM). In aged
aortas, increased levels ofmiR-29 familymemberswere causally asso-
ciated to the downregulation of ECM components, linkingmiR-29 to a
decrease in ECM proteins and the age-associated formation of aorta
aneurysms [53].
• SASP. Secretion of some SASP factors (e.g., IL-6, IL-8) is under control
of IRAK1, a protein whose levels are reduced by the senescence-
associated miR-146. Factors secreted through the SASP cause inﬂam-
mation, contributing to a general increase of inﬂammation also
termed “inﬂamm-ageing”. Accordingly, miR-146 has been shown to
be increased in senescent ECs [54] as well as in endothelial progenitor
cells (EPCs) from heart failure (HF) patients [55].
The fact that miR-126 controls endothelial inﬂammation, at least in
part by modulating the expression of VCAM-1 cell adhesion proteins
Fig. 1. Senescence-associated ncRNAs. Several studies have identiﬁed ncRNAs upregulated and downregulated in senescence, but only few have been shown to modulate senescence
experimentally. The ﬁgure shows microRNAs (blue) and lncRNAs (green) directly implicated in molecular pathways that govern cell senescence.
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associatedwith in CVDs and diabetes [57], two conditions characterized
by EC activation. These proinﬂammatory effects may also be linked to
miR-126-mediated downregulation of NFκBIB (IκBβ), a potent inhibitor
of NF-κB signaling [58]. High levels of miR-155 were found in proin-
ﬂammatory macrophages and atherosclerotic lesions, although the
effects of miR-155 appear to differ between early and advanced athero-
sclerosis [59]. Interestingly, miR-155 lowers angiotensin II type 1 recep-
tor (AT1R) activity leading to endothelial dysfunction, structural
remodeling, and vascular inﬂammation [60].
Certain senescence-associated miRNAs function at the convergence
of different pathways. For instance, miR-34a levels are increased
in aged hearts, but since cardiomyocytes are mostly post-mitotic, miR-
34a likely does not inﬂuence proliferation in these cells. Instead,
cardiomyocyte miR-34a lowers Ppp1r10 (PNUTS) [61], a protein that
interactswith the telomere regulator TRF2 to control DNA repair and re-
duce telomere attrition. PNUTS protects cardiomyocytes from oxidative
damage and death and both increased PNUTS and reduced miR-34a
prevent the deterioration of cardiac contractile function after AMI [61].
2.1.2. Fibrosis
Aging hearts are characterized by increased expression of ECM pro-
teins [62], ﬁbronectin [63], thrombospondin-2 (TSP-2) [64] and connec-
tive tissue growth factor (CTGF) [65]. These elevated levels are due, at
least in part, to the age-dependent accumulation of senescent cells in
these tissues, which promote inﬂammation and cardiac ﬁbrosis
[66–68]. Notably, miR-18a and miR-19a/b, from the miR-17–92 cluster,
are causally linked to age-related ﬁbrotic remodeling of the heart upon
HF [69]. TSP-1 and CTGF, which contribute to the ﬁbrotic process, are
targets of miR-18a and miR-19a and their levels are inversely
correlated.
Increased levels of miR-29 familymembers were causally associated
to the downregulation of ECM components in aged aortas, linking miR-
29 to the decrease in ECM proteins and the age-associated formation ofaorta aneurysms [53]. Fibrotic myocardium also shows high levels of
miR-21; by lowering the abundance of target protein SPRY2,miR-21 ac-
tivates signaling through ERK/MAPK, leading to increased ﬁbrosis and
decreased apoptosis [70]. The role of miR-21 in age-associated ﬁbrosis
has not been elucidated, but it is worth noting that miR-21 levels in-
crease in aged hearts [39]. Another microRNA linked to ﬁbrosis, miR-
30, targets the proﬁbrotic growth factor CTGF. The downregulation of
miR-30 in left ventricle hypertrophy is associated to increased produc-
tion of ECM components [71].2.1.3. Nutrient sensing pathways
Major metabolic pathways include those governed by insulin,
insulin-like growth factor 1 (IGF1), and target of rapamycin (TOR). Ex-
cessive food intake leading to secretion of insulin, which facilitates the
uptake of glucose to be stored as fat, the accumulation of visceral fat,
and insulin resistance, are major risk factors for CVDs [72,73], including
atherosclerosis [74–76]. The tendency of centenarians to maintain high
insulin sensitivity [77] suggests that systemic insulin/IGF1 pathway ac-
tivation itself confers protection from CVD in the absence of obesity.
The inﬂuence of miR-1 in IGF1 signaling in cardiomyocytes is well
documented. miR-1 directly represses IGF1mRNA in cardiac and skele-
talmuscle [78], andmiR-1 levels are inversely correlatedwith IGF1 pro-
tein levels in models of cardiac hypertrophy and failure [79]. In this
regard, Shan et al. [80] reported that the levels of IGF1 repressors miR-
1 and miR-206 increased in the ischemic zone in rat AMI. Overexpres-
sion of miR-1 or silencing of IGF1 in H9C2 rat cardiomyoblasts upon
serum withdrawal or hypoxia elevated caspase-3 activity and mito-
chondrial potential, in agreement with the anti-apoptotic function of
IGF1 [81,82].
Moderate caloric restriction (CR) without malnutrition is a dietary
regimen recognized to delay aging and extend lifespan [83]. In aged
ECs, miR-144 abundance increases while that of its predicted target
NF-E2-related factor 2 (Nrf2) decreases. This inﬂuence is potentially
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pro-angiogenic, and anti-inﬂammatory effects in mouse ECs [84].2.1.4. Oxidative stress
Mitochondrial dysfunction is another hallmark of aging-associated
diseases. As cells and organisms age, the efﬁcacy of the respiratory
chain declines, causing increased electron leakage and reduced ATP
generation [85]. Additionally, the production of reactive oxygen species
(ROS) by dysfunctional mitochondria can trigger cellular events culmi-
nating in a wide range of CVDs [86,87]. Different miRNAs modulated by
oxidative stress are involved in endothelial and vascular dysfunction
and are associated to CVDs caused by excessive ROS production [88].
miR-200, miR-141. miRNA proﬁling experiments have revealed that
the miR-200 family members miR-200c and miR-141 are upregulated
in hydrogen peroxide (H2O2)-treated ECs [89] (Fig. 2). Moreover, the
miR-200 family is also induced following acute ischemia, which gener-
ates oxidative stress [90]. Accordingly, in p66ShcA−/− mice, which
display lower levels of oxidative stress upon ischemia, miR-200c and
miR-200b are less upregulated [89]. The pro-survival protein ZEB1
was identiﬁed as a direct target of miR-200c, leading to the discovery
that ZEB1 knockdown recapitulated miR-200c-triggered responses
and that miR-200-mediated inhibition of ZEB1 was a key effector of
ROS-induced apoptosis and senescence. In keeping with the increased
oxidative stress levels observed in diabetes mellitus, miR-200c and
miR-141 are among the most upregulated miRNAs in diabetic mouse
heart [91]. The levels of miR-141-target SLC25A3 (solute carrier familyFig. 2.miR-200 regulates endothelial dysfunction and cardiovascular complications linked
to diabetes and obesity. ROS production or pathologies associated to elevated ROS produc-
tion play a causal role in endothelial and cardiovascular diseases. (Left)MiR-200c andmiR-
141 are among themost highly upregulatedmiRNAs in diabeticmouse heart; accordingly,
the target of miR-200 SLC25A3, a protein essential for ATP production, declines in type 1
diabetes, reducing ATP production and cell viability. (Center) In Zucker obese rats, a genet-
ic model for obesity, hypertension and cardiac dysfunction, elevated miR-200c activates a
compensatory mechanism to down-regulate excessive activation of the nutrient sensor
kinase S6K1, involved in adipocyte lineage commitment. (Right) MiR-200c levels rise
following oxidative stress; the ensuing inhibition of its target ZEB1 induces cell growth
arrest, apoptosis and cellular senescence.25member 3), whichprovides inorganic phosphate to themitochondri-
almatrix and is essential for ATP production, declines in type 1 diabetes,
affecting adversely ATP production and cell viability. Finally, miR-200c,
which is not normally expressed in heart, is readily detectable in the
heart of Zucker obese rats, where it participates in adaptivemechanisms
compensating excessive activation of the nutrient sensor kinase S6K1
[92].
miR-21. Treatment of rat vascular smoothmuscle cells (VSMCs)with
H2O2 elevated miR-21, which in turn protected VSMCs from H2O2-
dependent apoptosis and death. A major target of miR-21-mediated re-
pression is PDCD4 (Programmed cell death 4), a pro-apoptotic protein
that inhibits the activity of the transcription factor AP-1 [93], providing
a plausible mechanismwhereby elevatedmiR-21 protects ECs from ox-
idative injury. Among the factors triggering the development of athero-
sclerotic lesions are disturbances in ﬂow dynamics [94]. Shear stress
increases miR-21 levels, which contributes to protecting ECs by in-
creasing endothelial nitric oxide synthase (eNOS) and nitric oxide
(NO) production [95]. However, miR-21 function is complex and
context-dependent; in this regard, miR-21 has detrimental effects
in atherosclerotic plaques, where high levels of miR-21 decreases
the functions of the mitochondrial defense proteins SPRY2 and su-
peroxide dismutase-2 (SOD-2). These effects, in turn, lead to ERK/
MAPK activation, resulting in increased ROS levels and EPC migrato-
ry defects [96].
miR-145. After AMI, during ischemia–reperfusion injury, ROS typi-
cally causes oxidative stress in cardiomyocytes. Recently, Li et al.
found reduced miR-145 levels in both ischemia/reperfused heart and
H2O2-treated cardiomyocytes [97]. Given that miR-145 protected
against oxidative stress-induced cardiomyocyte apoptosis by inhibiting
expression of its target BNIP3 and by preventing ROS generation, miR-
145 was proposed to function as a cardioprotective molecule capable
of counteracting ROS toxicity.
miR-210. Another potent inducer of mitochondrial dysfunction and
oxidative stress is hypoxia [98].miR-210 is robustly induced by hypoxia,
contributing to the oxidative phosphorylation decline observed in low
oxygen by repressing ISCU1, ISCU2, COX10 and FECHmRNAs. These tran-
scripts, in turn, encode proteins which directly or indirectly affect the
mitochondrial respiratory chain [98]. Accordingly, miR-210 inhibition
triggered mitochondrial dysfunction, oxidative stress and increased tis-
sue damage upon ischemia [99] (Fig. 3).
2.1.5. Autophagy
Autophagy is a recycling mechanism whereby cells degrade unnec-
essary cytoplasmic material and organelles in lysosomes [100]. A de-
cline of the autophagy factors has been observed in aging tissues and
in age-related disorders [101,102]. Autophagy seems to play a protec-
tive role during atherosclerosis, because it stabilizes plaques through
the processing of oxidatively modiﬁed proteins, whereas acquired de-
fects in plaques autophagy exacerbate atherosclerosis [100]. Menghini
et al. [103] showed that expression of BECN1, ATG5 and LC3B-II/
MAP1LC3B, key autophagy-related proteins, decreased during EC senes-
cence, suggesting that the autophagic process is impaired with aging
(Fig. 4). They also showed that miR-216a was induced during endothe-
lial aging and that it was able to reduce the expression of BECN1 and
ATG5. As a consequence, miR-216 also regulated autophagy induced
by oxidized low-density lipoprotein (ox-LDL) treatment, stimulated
ox-LDL accumulation, and promoted monocyte adhesion in ECs. The
role of miR-216a seems to be particularly important not only in the de-
velopment of atherosclerosis, but also in HF, since miR-216a expression
in human failing hearts was inversely correlated with ejection fraction
and with expression levels of BECN1 and ATG5mRNAs [103].
2.1.6. SIRT1 pathway
The “Silent mating type information regulation 2 homolog” (sirtuin
1 or SIRT1) is an NAD+-dependent class III histone deacetylase
(HDAC) that can extend the lifespan of organisms and its levels are
Fig. 3.miR-210 regulates mitochondrial activity. miR-210 represses target ISCU1, ISCU2,
COX10 and FECHmRNAs, encoding proteins that directly or indirectly affect themitochon-
drial respiratory chain and reduce ROS production.
Fig. 4.miR-216a regulates autophagy. miR-216a activity on its targets BECN1 and ATG5
inhibits autophagy and stimulates ox-LDL accumulation in EC as well as monocyte
adhesion and migration.
Fig. 5. SIRT1 regulation bymiRNAs in ECs. miR-217 downregulates SIRT1 expression. This
leads to lower deacetylation of its targets FOXO1 and eNOS, rendering them inactive and
triggering senescence (left). By targeting SIRT1 expression, miR-132 decreases SREBP-1c
acetylation and increases its activity, promoting the accumulation of fatty acids and
cholesterol (center). In TGF-β-treated ECs, miR-212 reduces SIRT1 abundance, inhibits
endothelial migration and capillary tube formation, and stimulates Notch signaling via
NRARP (right).
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of stress-responsive transcription factors, co-regulators and enzymes,
thus playing a direct role inmetabolic control [106]. In ECs, SIRT1 upreg-
ulation and/or activation is associated with beneﬁcial effects on ECs,
while excessive ROS and aging decreases SIRT1 expression leading to
endothelial dysfunction [107].
2.1.6.1. miR-217. This miRNA shows increased plasma levels with
advancing age and decreased levels by CR in mouse [108]. Endothelial
senescence is affected by this age-associated increase in miR-217,
which lowers SIRT1 levels. In turn, decreasing SIRT1 levels promotes
the acetylation state of Forkhead box protein O1 (FoxO1) and eNOS, re-
ducing their activity [109] (Fig. 5). Accordingly, miR-217 correlates neg-
atively with SIRT1 expression levels in human atherosclerotic plaques
and with FOXO1 acetylation status [109].
2.1.6.2. miR-132. In ECs overexpressing miR-132, SIRT1 levels were re-
duced [110] (Fig. 5). By lowering SIRT1 abundance, miR-132 promotes
the accumulation of fatty acids and cholesterol in HUVEC cells. In
fact, SIRT1 was shown to deacetylate and hence inhibit the sterol regu-
latory element-binding protein (SREBP)-1c, decreasing its association
with lipogenic target genes [111]. In view of these data, SIRT1 may
be involved in the ﬁne-tuning of vascular endothelial proinﬂammatory
processes triggered by fatty acid accumulation in vessels.
MiR-132 belongs to the pro-hypertrophic miR-212/132 cluster. In
TGF-β-treated ECs, miR-212 expression levels increase, while the ex-
pression of its target SIRT1 decreases [112]. Inhibiting miR-212, but
not miR-132, restores endothelial migration and capillary tube forma-
tion upon TGF-β challenge, while overexpression of SIRT1 rescues
148 S. Greco et al. / Journal of Molecular and Cellular Cardiology 83 (2015) 142–155tube formation capacity inmiR-212 overexpressing ECs [112]. Morever,
SIRT1 deacetylates Notch, thereby inhibiting signaling through Notch,
which negatively regulates angiogenic functions [113]. The inhibition
of miR-212 partly normalizes TGF-β-induced overexpression of
NRARP (Notch-Regulated Ankyrin Repeat Protein), indicating that
TGF-β suppresses SIRT1 and activates Notch signaling in ECs, at least
in part, via miR-212 (Fig. 5).
2.1.6.3. miR-34a. This pleiotropic microRNA also regulates cellular
senescence and angiogenesis by reducing SIRT1 levels. miR-34a levels
increase and SIRT1 levels decrease in aging hearts and senescent ECs
[114]. The repression of SIRT1 by miR-34a also decreases the resistance
of Bone Marrow Cells (BMCs) to oxidative stress and lowers the ability
of EPCs to rescue heart function after AMI [115]. In EPCs, decreased
miR-34a due to statin treatment rescues SIRT1 levels, possibly contrib-
uting to the beneﬁcial effects of statins on endothelial function in
coronary artery disease (CAD) [116].
2.1.6.4. miR-195. In cardiomyocytes, the free fatty acid palmitate in-
creasesmiR-195 levels, which in turn lowers SIRT1 production and pro-
motes apoptosis, causing lipotoxic cardiomyopathy [117] (Fig. 6).
2.1.6.5. miR-199. As shown in cardiomyocytes, the hypoxia-regulated
miR-199a is another repressor of SIRT1 [118] (Fig. 6). Hypoxia acutely
lowers miR-199a abundance, causing rapid upregulation of its target
hypoxia inducible factor-1α (HIF-1α) and triggering p53-dependent
apoptosis. Similarly, inhibition of miR-199a during normoxia induces
HIF-1α and SIRT1, which in turn downregulates PHD2, required for
HIF-1α stabilization, and thus recapitulates hypoxia preconditioning.
2.2. lncRNAs
As previously noted, very little is known about lncRNAs and aging.
However, given the variety of functions and biological mechanisms reg-
ulated by lncRNAs and considering the rapid progress in our knowledgeFig. 6. SIRT1 regulation by miRNAs in cardiomyocytes. In cardiomyocytes, the free
fatty acid palmitate increases miR-195 levels, which in turn inhibits SIRT1 and promotes
ROS-triggered apoptosis (left). In hypoxic cardiomyocytes, downregulation of miR-199a
increases HIF-1α levels and p53-mediated cardiomyocyte apoptosis (center). In normoxic
cardiomyocytes, lowmiR-199a raises SIRT1 andHIF-1α levels, simulating preconditioning
(right).of lncRNAs, it is likely that lncRNAs will prove to affect aging broadly.
Here, we provide some emerging examples of lncRNAs implicated in
regulating key features of aging and their dysregulation in a variety of
age-related CVDs.
2.2.1. Senescence-associated long noncoding (SAL)RNAs
RNA-seqencing analysis of proliferating and senescent ﬁbroblasts
revealed numerous senescence-associated lncRNAs (SAL-RNAs) that
were differentially expressed in senescent cells; some lncRNAs had
been previously annotated, including antisense transcripts and
pseudogene-encoded transcripts, while many others were novel
lncRNAs [119] (Fig. 1). However, just as we have vastly incomplete
knowledge of lncRNA function in general, the impact of lncRNAs on se-
nescence is also almost entirely unknown. Some lncRNAs that are be-
ginning to be implicated in senescence are:
2.2.1.1. Naturally occurring antisense lncRNAs (NA-SAL-RNAs). Some NA-
SAL-RNAs showing higher expression levels in senescent cells
were those targeting the mRNAs that encode metallopeptidase
ADAMTS19 and the secreted protein osteocrin. On the other hand,
NA-SAL-RNAs less abundant in senescent cells targeted the mRNAs
encoding versican (an extracellularmatrix proteoglycan) and the limbic
system-associated membrane protein (LSAMP).
2.2.1.2. LncRNAs encoded by pseudogenes (PE-SAL-RNAs). PE-SAL-RNAs
more highly expressed in senescent cells included the carcinoembryonic
antigen-related cell adhesion molecules CEACAMP10 and CEACAMP11,
while PE-SAL-RNAs lower in senescent cells include transcripts
expressed from the ribosomal protein L21 pseudogene and from the
heterogeneous nuclear ribonucleoprotein A1 (HNRNPA1) pseudogene
[120].
2.2.1.3. Other previously annotated lncRNAs. Among the previously anno-
tated senescence-upregulated lncRNAs [119], HOTAIR functions as a
scaffold factor for the ubiquitination and subsequent degradation of
Ataxin-1 and Snurportin-1 mediated by E3 ubiquitin ligases [24]. By
contrast, the well-known lncRNAs MALAT1, XIST, and MIAT/GOMAFU
were less abundant in senescent cells. Silencing MALAT1 or MIAT en-
hanced cellular senescence, providing direct evidence that these
lncRNAs were implicated in senescence [119]. Additionally, DNA-dam-
age-activated p53 was necessary for the cell cycle arrest induced by
MALAT1 [121]. The inhibition of cellular senescence by lncRNA 7SL was
attributed, at least in part, to the repression of p53 translation by 7SL
[120].
2.2.1.4. Novel differentially abundant SAL-RNAs. Among the novel differ-
entially abundant SAL-RNAs identiﬁed in this screen, lncRNAs
XLOC_023166, XLOC_025931 and XLOC_ 025918 modulated the onset
of senescence and protected the viability of senescent cells [120].
2.2.2. LncRNAs and telomere shortening
Telomere shortening is a hallmark of aging and stress-induced
senescence [122]. Telomere length critically affects cell senescence
and organism life span. Accordingly, prevention of age-associated telo-
mere shortening by telomerase activation increases both health and
longevity [123]. A key component of the complex machinery regulating
telomere length and erosion is the lncRNA family TERRA. Transcribed
from the telomeres, TERRA lncRNAs associate with RNA-binding
proteins such as hnRNPA1 and regulate telomerase activity. Only
when the correct stoichiometry between TERRA and hnRNPA1 is
achieved, telomerase is free to elongate telomeres and avoid erosion
[124]. However, the impact of this mechanism upon age and age-
associated CVDs remains unknown.
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Even though the attention of the scientiﬁc community has only
started to focus on lncRNAs in the past few years, several lncRNAs
have been associated or causally linked to age-associated CVDs. Many
further studies will be needed to discriminate lncRNAs that drive
aging CVDs from those implicated only indirectly, but some information
is already beginning to accumulate.
Sustained cardiac hypertrophy is often followed by maladaptive
cardiac remodeling, which increases risk for HF. Recently, increased
levels of CHRFwere found in cardiomyocytes (CMs) treatedwith Angio-
tensin II (Ang II) to induce hypertrophy [125]. CHRF sponged and hence
reduced the function of miR-489, lowering its activity in hypertrophic
CMs; conversely, ectopic miR-489 expression in CMs and in transgenic
mice reduced the hypertrophic inﬂuence of Ang II treatment.
In Pdk1-nullmice, a differentmodel of HF, Liu et al. identiﬁed several
dysregulated lncRNAs [126]. Network and pathway analyses of these
lncRNAs highlighted the involvement of the MAPK signaling pathway,
which is causally involved in myocardial hypertrophy and HF [127].
Moreover, they identiﬁed MKK7, a sense overlapping lncRNA in the
proximity of MAP2K7 (implicated in both HF and hypertrophy [126,
128]), as being downregulated in CMs in Pdk1-null mice.
Concerning naturally occurring antisense lncRNAs, cardiac troponin
I (cTNI) is essential for normal sarcomere function in adult CMs and its
expression appears to be regulated by cTNI sense-antisense duplexes
[129]. Interestingly, cTNI expression levels correlate with ischemia and
risk of HF, but the role of the antisense transcript in disease has not
yet been evaluated.
Another interesting antisense lncRNA, NPPA-AS, modulates the
alternative splicing of the NPPA (natriuretic peptide precursor
A) pre-mRNA [130], which is usually expressed only in fetal atrial
and ventricular myocardium. NPPA is re-expressed in patients
exhibiting hypertrophy and HF [131], and is considered to be a mark-
er for heart disease.
Very recently, an elegant study inmice identiﬁed a cluster of nuclear,
cardiac-speciﬁc lncRNAs expressed from theMyh7 locus termedmyosin
heavy-chain-associated (Myheart orMhrt) RNAs [132].While abundant
in adult mouse myocardium, Mhrt RNAs were downregulated in
transaortic constriction (TAC)-induced HF, and this reduction coincided
with a characteristic Myh6-to-Myh7 isoform switch. Mhrt transcription
was inhibited by the Brg1–Hdac–Parp chromatin repressor complex 3,
was activated by stress, and was essential for cardiomyopathy develop-
ment. Accordingly, restoring Mhrt prevented heart hypertrophy and
failure, indicating that Mhrt has a protective role in CVDs [132].
Reperfusion therapy is frequently used as treatment for AMI [133,
134]. However, after reperfusion therapy, patients often suffer from
myocardial ischemia/reperfusion injury and oxidative stress [135]. The
levels of several lncRNAs are modulated at early stages of reperfusion
following ischemia [136]. Zangrando et al. [137] showed that AMI in
mice was associated with modulation of 30 lncRNAs; among these,
myocardial infarction-associated transcript 1 (MIRT1) and 2 (MIRT2)
lncRNAs showed robust upregulation. MIRT1 and MIRT2 expression
levels were negatively correlated with infarct size and positively corre-
lated with ejection fraction (EF). In addition,MIRT1 andMIRT2 correlat-
ed with the expression of multiple genes known to be involved in
processes affecting left ventricular remodeling, such as inﬂammation,
extracellular matrix turnover, ﬁbrosis and apoptosis.
Finally, the chromosomal locus 9p21, which contains one of the
strongest genetic susceptibility locus for CVDs and type 2 diabetes,
spans 50 kb of DNA that do not contain protein-coding genes but do
contain the lncRNA ANRIL (CDKN2A/INK4 locus) [138–141]. According-
ly, ANRIL expression is tightly regulated by the identiﬁed SNPs [142] and
ANRIL expression levels positively correlate with atherosclerosis severi-
ty [143]. However, as a word of caution,multiple ANRIL transcripts have
been identiﬁed (17 annotated in Ensembl so far, http://www.ensembl.
org/Homo_sapiens/Gene/Summary?db=core;g=ENSG00000240498;
r=9:21994778-22121097) and the results may differ among isoforms.Functional studies showed thatANRIL expression stimulates cell pro-
liferation, promotes adhesion, and decreases apoptosis, providing a po-
tential disease mechanism, at least for atherosclerosis [144]. From a
molecular perspective, ANRIL like several other lncRNAs, recruits
Polycomb repressive complexes 1 and 2 and Polycomb-associated acti-
vating proteins RYBP and YY1, inﬂuencing gene expression both in cis
and in trans [141].3. Circulating ncRNAs
As illustrated in the previous sections, signiﬁcant changes of tissue
ncRNA ‘signatures’ occur in various diseases, including CVDs. However,
routine biopsies for miRNA and/or lncRNA proﬁling are not clinically
feasible. Given that some miRNAs are released from the cells of origin
and can be measured in bodily ﬂuids [145,146], extracellular miRNAs
are remarkably stable in the circulation [147–150], and disease-
speciﬁc miRNA signatures can be identiﬁed in ﬂuids [151,152], investi-
gators are turning to less invasive approaches such as miRNA bio-
markers in circulation (e.g., in plasma or serum) [153–159]. Since
distal tissues can take up circulatingmiRNAs, theymay represent an im-
portant form of cell-to-cell communication [61,160,161]. Furthermore,
very recent evidence show that lncRNAs are present in plasma/serum
as well, and may potentially be used as biomarkers [146,162]. Plasma
or serum ncRNA identiﬁed in age-related CVD are summarized in
Table 2.3.1. Circulating microRNAs
3.1.1. MI
Altered levels of circulating miRNAs were detected in patients with
AMI, some elevated (miR-1, miR-133, miR-208a/b, miR-499, miR-
328), and some reduced (let-7b, miR-126) [153,163,164]. Many upreg-
ulated plasmamiRNAswere highly expressed inmyocytes and correlat-
ed with plasma cardiac troponin T (cTnT), suggesting that they were
released from injured cardiomyocytes.
In an interesting commentary, Cui and Zao highlighted the impor-
tance of selecting the proper control group in this kind of studies and
in general in all investigations aimed at identifying diagnostic markers
[165]. Using healthy people as control groupmight artifactually increase
the speciﬁcity of thediagnostic tests. Indeed, in clinical practice, patients
often suffer from various other diseases, some of which might impact
upon the biomarker under investigation.
Only a few studies have explored the speciﬁc circulating microRNAs
in geriatric patients. In acute non-ST segment elevation myocardial in-
farction (NSTEMI) of the elderly, circulatingmiR-499-5p displayed a di-
agnostic accuracy superior to that of cTnT in patients with modest
elevation at presentation [166]. Furthermore, circulating miR-499-5p
levels were associated with 12-month cardiovascular mortality after
NSTEMI in elderly subjects [167].3.1.2. CAD
Plasma levels of EC-enriched miRNAs (miR-126, miR-17, and miR-
92a), inﬂammation-associated miR-155, and smooth muscle-enriched
miR-145 were reported to be signiﬁcantly reduced in stable CAD pa-
tients compared to healthy controls [153,154,158,168,169]. In addition,
miR-135a and miR-147 levels were found to be increased and de-
creased, respectively, in peripheral blood mononuclear cells (PBMCs)
from CAD patients. Recently, miR-337-5p, miR-433, and miR-485-3p
expression levels were shown to be higher in CAD patients [170]. Inter-
estingly, increased levels of miR-134, miR-198 and miR-370 [171], as
well as miR-106b, miR-25, miR-92a, miR-21, miR-590-5p, miR-126*
and miR-451 [162] were able to discriminate unstable from stable
angina pectoris, suggesting that this miRNA signature could be used to
identify patients at risk for acute coronary syndromes.
Table 2
Circulating ncRNAs and ncRNAs in age-related cardiovascular diseases.
Disease/condition Modulation Refs
miR-1 Myocardial infarction Up [191–194]
miR-133 Myocardial infarction Up [159,192]
miR-208a Myocardial infarction Up [193]
miR-208b Myocardial infarction Up [173,193]
miR-499 Myocardial infarction Up [166,193,194]
miR-328 Myocardial infarction Up [195]
miR-27b Myocardial infarction Down [196]
miR-126 Myocardial infarction Down [197]
miR-126, miR-92a, miR-17, miR-155, and miR-145 Coronary artery disease Down [198]
miR-147 Coronary artery disease Down [171]
miR-135 Coronary artery disease Up [171]
miR-337-5p, miR-433, and miR-485-3p Coronary artery disease Up [170]
miR-134, miR-198, and miR-370, Unstable angina vs stable angina Up [171]
miR-106b, miR-25, miR-92a, miR-21, miR-590-5p, miR-126*, and miR-451 Unstable angina vs stable angina Up [162]
miR-423-3p Heart failure Up [172]
miR-499, -122 Heart failure Up [173]
miR-126 Heart failure Down [57]
miR-107, miR-139, miR-142-5p, miR-125b, and miR-497 Heart failure Down [174]
miR-142-3p, miR-29b Heart failure Up [174]
miR-503 t2dm + critical limb ischemia Up [175]
ANRIL Myocardial infarction Down [179]
aHIF Myocardial infarction Up [179]
ANRIL, KCNQ1OT1 Myocardial infarction Down [179]
LIPCAR Myocardial infarction Down [181]
150 S. Greco et al. / Journal of Molecular and Cellular Cardiology 83 (2015) 142–1553.1.3. HF
A plethora of miRNAs have been found to be dysregulated in HF
[153,154,158,168,169]: a) miR-423-5p, which correlates signiﬁcantly
with brain natriuretic peptide (BNP) levels and left ventricular ejection
fraction [172]; b) elevated concentrations of miR-499 and miR-122 in
acute HF [173]; and c) decreased levels of miR-126 in chronic HF,
which correlated inversely with age and disease severity [57]. In
addition, proﬁling PBMC miRNAs in both ischemic (ICM) and non-
ischemic dilated cardiomyopathy (NIDCM) patients showed that miR-
107, miR-139, and miR-142-5p levels were low in both HF classes,
miR-142-3p and miR-29b levels increased only in NIDCM patients,
andmiR-125b andmiR-497 levels decreased only in ICM patients [174].
3.1.4. Impaired peripheral angiogenesis
miR-503 contributed to the impaired peripheral angiogenic signaling
in patients with type 2 diabetes mellitus (T2DM) and miR-503 plasma
levels were elevated in diabetic patients with critical limb ischemia [175].
Finally, studies of the effects of CR on serum miRNAs in young and
aged control mice have identiﬁed sets of miRNAs displaying increased
levels with age and antagonization of this increase by CR [108]. Interest-
ingly, the proteins predicted to be repressed by this set of age-
modulated miRNAs are implicated in age-relevant biological processes,
including metabolic changes [176–178]. It is tempting to speculate that
serum miRNAs may participate in age-induced changes in physiology
and pathology, and that their modulation may underlie, at least in
part, the anti-aging effects of CR.
3.2. Circulating lncRNAs
Data on circulating lncRNAs are still emerging, and some of them are
related to CVDs; however, so far, only one lncRNA was linked to aging.
Vausort et al. [179] identiﬁed 5 dysregulated lncRNAs in peripheral
blood cells of MI patients: aHIF, ANRIL, KCNQ1OT1, MIAT and MALAT1.
The levels of aHIF, KCNQ1OT1 and MALAT1 were higher in AMI patients
than in healthy volunteers, while the levels of ANRIL were lower in AMI
patients. Patients with ST-elevation myocardial infarction (STEMI) had
lower levels of ANRIL,KCNQ1OT1,MIAT andMALAT1 compared to patients
with non-STEMI patients. Lower levels of ANRILwere associated with ad-
vancing age, diabetes, and hypertension, while ANRIL and KCNQ1OT1 im-
proved the prediction of left ventricular dysfunction [179].Using microarrays, Li et al. [180] found several lncRNAs modulated
in a mouse model of HF; 32 among these were simultaneously
expressed in the heart, whole blood, and plasma, indicating their poten-
tial usefulness as HF biomarkers.
In global transcriptomic analyses on plasma RNA from patients with
and without left ventricular remodeling after AMI, the mitochondrial
lncRNA uc022bqs.1 (renamed LIPCAR) was found downregulated early
after AMI but upregulated at later times following AMI [181]. Measure-
ment of LIPCAR levels was successfully used to stratify patients with re-
spect to their risk of developing cardiac remodeling, and to predict
cardiac remodeling and cardiovascular death after HF.
4. Challenges and opportunities
Although the clinical value of ncRNAs is only beginning to surface,
the available data already highlight opportunities for ncRNA-based
therapies in age-related CVDs. MicroRNAs represent particularly attrac-
tive therapeutic targets, since they can be easily synthesized in both
sense and antisense (inhibitory) orientation, modiﬁed for stability,
and attached to medical devices and biomaterials. Strategies can be
envisioned using ncRNAs as the therapeutic agents to be delivered ec-
topically. Reciprocally, the aim can also be to repress or neutralize path-
ologic endogenous ncRNAs. Preclinical studies adopting these
approaches are summarized in Table 3.
While no human experimentation targeting miRNAs has been
started yet for CVDs, a phase I clinical trial for cancer therapy is ongoing
using a mimic of miR-34a named MRX34 (ClinicalTrials.gov Identiﬁer:
NCT01829971). MRX34 is a liposome-formulated mimic of miR-34a, a
microRNA showing decreased levels in many tumor types [182]. More-
over, the applicability of miRNA inhibition as a therapeutic tool is con-
ﬁrmed by the successful completion of a phase IIa clinical trial based
on anti-miR-122 (NCT01200420) [183]. This study showed that locked
nucleic acid (LNA)-anti-miRNA developed for hepatitis C therapy is ef-
fective, safe, and well tolerated.
LNA modiﬁcations might also be useful for inhibiting lncRNAs with
GapmeRs, antisense oligonucleotides that contain a central stretch
(gap) of DNAmonomersﬂanked by blocks of LNA-modiﬁed nucleotides.
The LNA-nucleotides increase the afﬁnity for a target RNA and stability
of the oligonucleotide, while the DNA forms a duplex DNA-RNA that is
cleaved by RNaseH. This tool is particularly useful to target nuclear tran-
scripts that are poor RNAi substrates [184].
Table 3
Effects of the administration of miRNAs and anti-miRNAs in animal models of CVDs.
miR Intervention Effects Refs
miR-15 Inhibition Infarct size reduction, cardiac remodeling, cardiac function improvement [199]
miR ~ 17–92 KO Reduced proliferation [200]
miR-24 Inhibition Infarct size reduction, cardiac and vascular function improvement [201]
miR-29b Inhibition Reduced ﬁbrosis [202]
miR-320 Inhibition Infarct size reduction [203]
miR-590/199a Overexpression Infarct size reduction, cardiac function improvement [204]
miR-208a KO, transgenic Inhibition Hypertrophy reduction after trans-aorta binding
Cardiac remodeling reduction in Dahl rats
[205]
[206]
[207]
miR-132/212 family Inhibition, KO Protection from pressure overload-induced heart failure [208]
miR-133 Inhibition Induction of cardiac hypertrophy [209]
miR-21 Inhibition Fibrosis reduction after pressure overload [70]
miR-101a/b Overexpression Fibrosis reduction after infarction [210]
miR-24 Inhibition Prevention of decompensated hypertrophy [211]
miR-22 KO Prevention of hypertrophy and remodeling [212]
miR-199b Inhibition Prevention of hypertrophy and ﬁbrosis in HF mouse model [213]
miR-378 Overexpression Hypertrophy reduction after thoracic aortic constriction [214]
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egies for ncRNA-based therapy, including the optimization of delivery
systems and the chemistry of the therapeutic molecule. These obstacles
are particularly challenging for lncRNAs, since they are longer, bulkier,
and more labile. However, some of the lessons learned with mRNA-
based gene therapy might prove useful for lncRNA-based interventions
[185–187].
Delivering miRNAs as therapeutic agents offers a powerful tool for
ﬁne-tuning target proteins or pathways. A major potential drawback
of this approach is the fact that one miRNA can theoretically affect
many biological processes, not just a single gene product. However,
this feature of microRNAs could be exploited for therapeutic gain in
aging dysfunction and disease, if we wish to intervene in the broader
molecular pathways regulated by the speciﬁc miRNA. To take full
advantage of this trait, we must ﬁrst understand in detail the actions
of the miRNA in a relevant pathological context, before progressing to
clinical application.
Abbreviations
1/2-sbsRNAs half-STAU1-binding site RNAs
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ATG5 autophagy-related 5
BCL-2 B-cell lymphoma 2
BECN BECLIN 1, autophagy-related
B-MYB v-myb avian myeloblastosis viral oncogene homolog-like 2
BNIP3 BCL2/adenovirus E1B 19 kDa protein-interacting protein 3
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CDKN2A/INK4 cyclin-dependent kinase inhibitor 2A
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pseudogene
CHFR cardiac hypertrophy related factor
COX10 cytochrome c oxidase assembly homolog 10
ERK extracellular signal-regulated kinase
FECH Ferrochelatase
FIRRE functional intergenic repeating RNA element
GAS5 growth arrest-speciﬁc 5
GMC-SF granulocyte macrophage colony-stimulating factor
HDAC histone deacetylase
HMGA2 high-mobility group AT-hook 2
HOTAIR HOX transcript antisense RNA
Id DNA-binding protein, inhibitor
IGF1 insulin-like growth factor 1IL1α interleukin 1α
IL-6 interleukin 6
IL-8 interleukin 8
IRAK1 interleukin-1 receptor-associated kinase 1
ISCU iron–sulfur cluster assembly enzyme 1
KCNQ1OT1 potassium voltage-gated channel, KQT-like subfamily,
member 1 opposite strand 1
LC3B-II/MAP1LC3B microtubule-associated protein 1 light chain 3
beta-II
LincRNA long intervening noncoding RNA
LINCMD1 long noncoding RNA, muscle differentiation
MALAT1 metastasis associated lung adenocarcinoma transcript 1
MAPK mitogen-activated protein kinase
MCM5 minichromosome maintenance complex component 5
MDC1 mediator of DNA-damage checkpoint protein 1
MI myocardial infarction
MIAT/GOMAFU myocardial infarction-associated transcript
MKK7 MAP kinase kinase 7
MMP-1 matrix metalloproteinase-1
MMP-3 matrix metalloproteinase-3
MYH6 myosin, heavy chain 6, cardiac muscle, alpha
MYH7 myosin, heavy chain 7, cardiac muscle, beta
NAD+ nicotinamide adenine dinucleotide
NEAT1 nuclear enriched abundant transcript 1
NFκBIB nuclear factor of kappa light polypeptide gene enhancer in B
cells inhibitor, beta
NF-κB nuclear factor of kappa light polypeptide gene enhancer in B
cells
NPPA natriuretic peptide A
NPPA-AS natriuretic peptide A antisense RNA
NRARP notch-regulated ankyrin repeat protein
Nrf2 NF-E2 related factor 2
PARP poly (ADP-ribose) polymerase
PCGF4 polycomb group RING ﬁnger protein 4
Pdk1 pyruvate dehydrogenase kinase, isozyme 1
Ppp1r10 protein phosphatase 1, regulatory subunit 10
RAR-γ retinoic acid receptor gamma
RB retinoblastoma protein
S6K1 ribosomal protein S6 kinase 1
ShcA Src homology 2 domain-containing
SIRT1 silent mating type information regulation 2 homolog
SPRY2 sprouty homolog 2
SREBP-1c sterol regulatory element-binding protein
TERRA telomeric repeat-containing RNA
TRF2 telomeric repeat binding factor 2
TUG1 taurine upregulated gene 1
XIST X-inactive speciﬁc transcript
152 S. Greco et al. / Journal of Molecular and Cellular Cardiology 83 (2015) 142–155ZEB1 zinc ﬁnger E-box binding homeobox 1
γ-H2AX gamma-H2A histone family, member XDisclosures
None.Acknowledgments
This study was supported by Ministero della Salute (SG and FM),
Fondazione Cariplo grant #2013-0887 (SG and FM) and Telethon-Italy
GGP14092 (FM). KMKim assisted with illustrations. MGwas supported
by the NIA-IRP, NIH (AG000393-07).References
[1] Cech TR, Steitz JA. The noncoding RNA revolution-trashing old rules to forge new
ones. Cell 2014;157:77–94.
[2] Salmanidis M, Pillman K, Goodall G, Bracken C. Direct transcriptional regulation by
nuclear microRNAs. Int J Biochem Cell Biol 2014;54c:304–11.
[3] Yoon JH, Abdelmohsen K, Gorospe M. Posttranscriptional gene regulation by long
noncoding RNA. J Mol Biol 2013;425:3723–30.
[4] Krol J, Loedige I, Filipowicz W. The widespread regulation of microRNA biogenesis,
function and decay. Nat Rev Genet 2010;11:597–610.
[5] Djebali S, Davis CA, Merkel A, Dobin A, Lassmann T, Mortazavi A, et al. Landscape of
transcription in human cells. Nature 2012;489:101–8.
[6] Li L, Chang HY. Physiological roles of long noncoding RNAs: insight from knockout
mice. Trends Cell Biol 2014;24:594–602.
[7] Small EM, Olson EN. Pervasive roles of microRNAs in cardiovascular biology. Nature
2011;469:336–42.
[8] Chen LH, Chiou GY, Chen YW, Li HY, Chiou SH. MicroRNA and aging: a novel mod-
ulator in regulating the aging network. Ageing Res Rev 2010;9(Suppl. 1):S59–66.
[9] Fabian MR, Sonenberg N, FilipowiczW. Regulation of mRNA translation and stabil-
ity by microRNAs. Annu Rev Biochem 2010;79:351–79.
[10] Ha M, Kim VN. Regulation of microRNA biogenesis. Nat Rev Mol Cell Biol 2014;15:
509–24.
[11] Gorospe M, Abdelmohsen K. MicroRegulators come of age in senescence. Trends
Genet 2011;27:233–41.
[12] Jansson MD, Lund AH. MicroRNA and cancer. Mol Oncol 2012;6:590–610.
[13] Fiore R, Siegel G, Schratt G. MicroRNA function in neuronal development, plasticity
and disease. Biochim Biophys Acta 2008;1779:471–8.
[14] Kung JT, Colognori D, Lee JT. Long noncoding RNAs: past, present, and future. Ge-
netics 2013;193:651–69.
[15] Spitale RC, Tsai MC, Chang HY. RNA templating the epigenome: long noncoding
RNAs as molecular scaffolds. Epigenetics 2011;6:539–43.
[16] Lee JT. Epigenetic regulation by long noncoding RNAs. Science 2012;338:1435–9.
[17] Bergmann JH, Spector DL. Long non-coding RNAs: modulators of nuclear structure
and function. Curr Opin Cell Biol 2014;26:10–8.
[18] Gong C, Maquat LE. lncRNAs transactivate STAU1-mediated mRNA decay by
duplexing with 3′ UTRs via Alu elements. Nature 2011;470:284–8.
[19] Yoon JH, Abdelmohsen K, Srikantan S, Yang X, Martindale JL, De S, et al. LincRNA-
p21 suppresses target mRNA translation. Mol Cell 2012;47:648–55.
[20] Mattick JS. Long noncoding RNAs in cell and developmental biology. Semin Cell
Dev Biol 2011;22:327.
[21] Anko ML, Neugebauer KM. Long noncoding RNAs add another layer to pre-mRNA
splicing regulation. Mol Cell 2010;39:833–4.
[22] Cesana M, Cacchiarelli D, Legnini I, Santini T, Sthandier O, Chinappi M, et al. A long
noncoding RNA controls muscle differentiation by functioning as a competing en-
dogenous RNA. Cell 2011;147:358–69.
[23] Tay Y, Rinn J, Pandolﬁ PP. The multilayered complexity of ceRNA crosstalk and
competition. Nature 2014;505:344–52.
[24] Yoon JH, Abdelmohsen K, Kim J, Yang X, Martindale JL, Tominaga-Yamanaka K,
et al. Scaffold function of long non-coding RNA HOTAIR in protein ubiquitination.
Nat Commun 2013;4:2939.
[25] Wapinski O, Chang HY. Long noncoding RNAs and human disease. Trends Cell Biol
2011;21:354–61.
[26] Harries LW. Long non-coding RNAs and human disease. Biochem Soc Trans 2012;
40:902–6.
[27] Mozaffarian D, Afshin A, Benowitz NL, Bittner V, Daniels SR, Franch HA, et al. Pop-
ulation approaches to improve diet, physical activity, and smoking habits: a scien-
tiﬁc statement from the American Heart Association. Circulation 2012;126:
1514–63.
[28] Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, et al. Global and re-
gional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a
systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012;
380:2095–128.
[29] Shioi T, Inuzuka Y. Aging as a substrate of heart failure. J Cardiol 2012;60:423–8.
[30] Dai DF, Rabinovitch PS, Ungvari Z. Mitochondria and cardiovascular aging. Circ Res
2012;110:1109–24.[31] Csiszar A, Ungvari Z, Edwards JG, Kaminski P, Wolin MS, Koller A, et al. Aging-
induced phenotypic changes and oxidative stress impair coronary arteriolar func-
tion. Circ Res 2002;90:1159–66.
[32] Lakatta EG. Arterial and cardiac aging:major shareholders in cardiovascular disease
enterprises: part III: cellular and molecular clues to heart and arterial aging. Circu-
lation 2003;107:490–7.
[33] Gimbrone Jr MA, Topper JN, Nagel T, Anderson KR, Garcia-Cardena G. Endothelial
dysfunction, hemodynamic forces, and atherogenesis. Ann N Y Acad Sci 2000;
902:230–9 [discussion 9–40].
[34] Ungvari Z, Sonntag WE, Csiszar A. Mitochondria and aging in the vascular system. J
Mol Med 2010;88:1021–7.
[35] Lakatta EG, Levy D. Arterial and cardiac aging: major shareholders in cardiovascular
disease enterprises: part I: aging arteries: a “set up” for vascular disease. Circulation
2003;107:139–46.
[36] Lee HY, Oh BH. Aging and arterial stiffness. Circ J 2010;74:2257–62.
[37] Kato M, Slack FJ. Ageing and the small, non-coding RNA world. Ageing Res Rev
2013;12:429–35.
[38] Harries LW. MicroRNAs as mediators of the ageing process. Genes 2014;5:656–70.
[39] Zhang X, Azhar G, Wei JY. The expression of microRNA and microRNA clusters in
the aging heart. PLoS ONE 2012;7:e34688.
[40] Hayﬂick L. The limited in vitro lifetime of human diploid cell strains. Exp Cell Res
1965;37:614–36.
[41] Kuilman T, Michaloglou C, Mooi WJ, Peeper DS. The essence of senescence. Genes
Dev 2010;24:2463–79.
[42] Campisi J. Senescent cells, tumor suppression, and organismal aging: good citizens,
bad neighbors. Cell 2005;120:513–22.
[43] Rodier F, Campisi J. Four faces of cellular senescence. J Cell Biol 2011;192:547–56.
[44] Tyner SD, Venkatachalam S, Choi J, Jones S, Ghebranious N, Igelmann H, et al. p53mu-
tant mice that display early ageing-associated phenotypes. Nature 2002;415:45–53.
[45] Baker DJ, Wijshake T, Tchkonia T, LeBrasseur NK, Childs BG, van de Sluis B, et al.
Clearance of p16Ink4a-positive senescent cells delays ageing-associated disorders.
Nature 2011;479:232–6.
[46] FentonM, Barker S, Kurz DJ, Erusalimsky JD. Cellular senescence after single and re-
peated balloon catheter denudations of rabbit carotid arteries. Arterioscler Thromb
Vasc Biol 2001;21:220–6.
[47] Minamino T, Miyauchi H, Yoshida T, Ishida Y, Yoshida H, Komuro I. Endothelial cell
senescence in human atherosclerosis: role of telomere in endothelial dysfunction.
Circulation 2002;105:1541–4.
[48] Abdelmohsen K, Kuwano Y, Kim HH, Gorospe M. Posttranscriptional gene regula-
tion by RNA-binding proteins during oxidative stress: implications for cellular se-
nescence. Biol Chem 2008;389:243–55.
[49] Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell 2009;136:
215–33.
[50] Borgdorff V, Lleonart ME, Bishop CL, Fessart D, Bergin AH, Overhoff MG, et al. Mul-
tiple microRNAs rescue from Ras-induced senescence by inhibiting p21(Waf1/
Cip1). Oncogene 2010;29:2262–71.
[51] Marasa BS, Srikantan S, Masuda K, Abdelmohsen K, Kuwano Y, Yang X, et al. In-
creased MKK4 abundance with replicative senescence is linked to the joint reduc-
tion of multiple microRNAs. Sci Signal 2009;2:ra69.
[52] Afanasyeva EA, Mestdagh P, Kumps C, Vandesompele J, Ehemann V, Theissen J,
et al. MicroRNA miR-885-5p targets CDK2 and MCM5, activates p53 and inhibits
proliferation and survival. Cell Death Differ 2011;18:974–84.
[53] Boon RA, Seeger T, Heydt S, Fischer A, Hergenreider E, Horrevoets AJ, et al.
MicroRNA-29 in aortic dilation: implications for aneurysm formation. Circ Res
2011;109:1115–9.
[54] Olivieri F, Lazzarini R, Recchioni R, Marcheselli F, Rippo MR, Di Nuzzo S, et al. MiR-
146a as marker of senescence-associated pro-inﬂammatory status in cells involved
in vascular remodelling. Age (Dordr) 2013;35:1157–72.
[55] Olivieri F, Spazzafumo L, Santini G, Lazzarini R, Albertini MC, Rippo MR, et al. Age-
related differences in the expression of circulating microRNAs: miR-21 as a new
circulating marker of inﬂammaging. Mech Ageing Dev 2012;133:675–85.
[56] Asgeirsdottir SA, van Solingen C, Kurniati NF, Zwiers PJ, Heeringa P, van Meurs M,
et al. MicroRNA-126 contributes to renal microvascular heterogeneity of VCAM-1
protein expression in acute inﬂammation. Am J Physiol Renal Physiol 2012;302:
F1630–9.
[57] Fukushima Y, Nakanishi M, Nonogi H, Goto Y, Iwai N. Assessment of plasma
miRNAs in congestive heart failure. Circ J 2011;75:336–40.
[58] Feng X, Wang H, Ye S, Guan J, Tan W, Cheng S, et al. Up-regulation of microRNA-
126 may contribute to pathogenesis of ulcerative colitis via regulating NF-kappaB
inhibitor IkappaBalpha. PLoS ONE 2012;7:e52782.
[59] Wei Y, Nazari-Jahantigh M, Neth P, Weber C, Schober A. MicroRNA-126, -145, and
-155: a therapeutic triad in atherosclerosis? Arterioscler Thromb Vasc Biol 2013;
33:449–54.
[60] Kim S, Iwao H. Molecular and cellular mechanisms of angiotensin II-mediated car-
diovascular and renal diseases. Pharmacol Rev 2000;52:11–34.
[61] Boon RA, Iekushi K, Lechner S, Seeger T, Fischer A, Heydt S, et al. MicroRNA-34a
regulates cardiac ageing and function. Nature 2013;495:107–10.
[62] Bradshaw AD, Baicu CF, Rentz TJ, Van Laer AO, Bonnema DD, Zile MR. Age-
dependent alterations in ﬁbrillar collagen content and myocardial diastolic func-
tion: role of SPARC in post-synthetic procollagen processing. Am J Physiol Heart
Circ Physiol 2010;298:H614–22.
[63] Burgess ML, McCrea JC, Hedrick HL. Age-associated changes in cardiac matrix and
integrins. Mech Ageing Dev 2001;122:1739–56.
[64] Swinnen M, Vanhoutte D, Van Almen GC, Hamdani N, Schellings MW, D'Hooge J,
et al. Absence of thrombospondin-2 causes age-related dilated cardiomyopathy.
Circulation 2009;120:1585–97.
153S. Greco et al. / Journal of Molecular and Cellular Cardiology 83 (2015) 142–155[65] Wang M, Zhang J, Walker SJ, Dworakowski R, Lakatta EG, Shah AM. Involvement of
NADPH oxidase in age-associated cardiac remodeling. J Mol Cell Cardiol 2010;48:
765–72.
[66] St John Sutton M, Pfeffer MA, Moye L, Plappert T, Rouleau JL, Lamas G, et al. Cardio-
vascular death and left ventricular remodeling two years after myocardial infarc-
tion: baseline predictors and impact of long-term use of captopril: information
from the Survival and Ventricular Enlargement (SAVE) trial. Circulation 1997;96:
3294–9.
[67] Gould KE, Taffet GE, Michael LH, Christie RM, Konkol DL, Pocius JS, et al.
Heart failure and greater infarct expansion in middle-aged mice: a relevant
model for postinfarction failure. Am J Physiol Heart Circ Physiol 2002;282:
H615–21.
[68] Minamino T, Komuro I. Vascular cell senescence: contribution to atherosclerosis.
Circ Res 2007;100:15–26.
[69] van Almen GC, Verhesen W, van Leeuwen RE, van de Vrie M, Eurlings C, Schellings
MW, et al. MicroRNA-18 and microRNA-19 regulate CTGF and TSP-1 expression in
age-related heart failure. Aging Cell 2011;10:769–79.
[70] Thum T, Gross C, Fiedler J, Fischer T, Kissler S, Bussen M, et al. MicroRNA-21 con-
tributes to myocardial disease by stimulating MAP kinase signalling in ﬁbroblasts.
Nature 2008;456:980–4.
[71] Duisters RF, Tijsen AJ, Schroen B, Leenders JJ, Lentink V, van der Made I, et al. miR-
133 and miR-30 regulate connective tissue growth factor: implications for a role of
microRNAs in myocardial matrix remodeling. Circ Res 2009;104:170–8 [6p follow-
ing 8].
[72] Oldham S. Obesity and nutrient sensing TOR pathway in ﬂies and vertebrates:
Functional conservation of genetic mechanisms. Trends Endocrinol Metab 2011;
22:45–52.
[73] Curtis B, Lage MJ. Glycemic control among patients with type 2 diabetes who
initiate basal insulin: a retrospective cohort study. J Med Econ 2014;17:
21–31.
[74] Bornfeldt KE. 2013 Russell Ross memorial lecture in vascular biology: cellular and
molecular mechanisms of diabetes mellitus-accelerated atherosclerosis.
Arterioscler Thromb Vasc Biol 2014;34:705–14.
[75] Yu Q, Gao F, Ma XL. Insulin says NO to cardiovascular disease. Cardiovasc Res 2011;
89:516–24.
[76] Cersosimo E, DeFronzo RA. Insulin resistance and endothelial dysfunction: the road
map to cardiovascular diseases. Diabetes Metab Res Rev 2006;22:423–36.
[77] Curtis R, Geesaman BJ, DiStefano PS. Ageing and metabolism: drug discovery op-
portunities. Nat Rev Drug Discov 2005;4:569–80.
[78] Yu XY, Song YH, Geng YJ, Lin QX, Shan ZX, Lin SG, et al. Glucose induces apoptosis of
cardiomyocytes via microRNA-1 and IGF-1. Biochem Biophys Res Commun 2008;
376:548–52.
[79] Elia L, Contu R, Quintavalle M, Varrone F, Chimenti C, Russo MA, et al. Reciprocal
regulation of microRNA-1 and insulin-like growth factor-1 signal transduction cas-
cade in cardiac and skeletal muscle in physiological and pathological conditions.
Circulation 2009;120:2377–85.
[80] Shan ZX, Lin QX, Fu YH, Deng CY, Zhou ZL, Zhu JN, et al. Upregulated expression of
miR-1/miR-206 in a rat model of myocardial infarction. Biochem Biophys Res
Commun 2009;381:597–601.
[81] Li Y, Higashi Y, Itabe H, Song YH, Du J, Delafontaine P. Insulin-like growth factor-1
receptor activation inhibits oxidized LDL-induced cytochrome C release and apo-
ptosis via the phosphatidylinositol 3 kinase/Akt signaling pathway. Arterioscler
Thromb Vasc Biol 2003;23:2178–84.
[82] Delafontaine P, Brink M. The growth hormone and insulin-like growth factor 1 axis
in heart failure. Ann Endocrinol 2000;61:22–6.
[83] Ungvari Z, Parrado-Fernandez C, Csiszar A, de Cabo R. Mechanisms underlying ca-
loric restriction and lifespan regulation: implications for vascular aging. Circ Res
2008;102:519–28.
[84] Valcarcel-Ares MN, Gautam T, Warrington JP, Bailey-Downs L, Sosnowska D, de
Cabo R, et al. Disruption of Nrf2 signaling impairs angiogenic capacity of endothe-
lial cells: implications for microvascular aging. J Gerontol A: Biol Med Sci 2012;67:
821–9.
[85] Green DR, Galluzzi L, Kroemer G. Mitochondria and the autophagy-inﬂammation-
cell death axis in organismal aging. Science 2011;333:1109–12.
[86] Napoli C, de Nigris F, Palinski W. Multiple role of reactive oxygen species in the ar-
terial wall. J Cell Biochem 2001;82:674–82.
[87] Tsutsui H, Kinugawa S, Matsushima S. Oxidative stress and heart failure. Am J Phys-
iol Heart Circ Physiol 2011;301:H2181–90.
[88] Magenta A, Greco S, Gaetano C, Martelli F. Oxidative stress and microRNAs in vas-
cular diseases. Int J Mol Sci 2013;14:17319–46.
[89] Magenta A, Cencioni C, Fasanaro P, Zaccagnini G, Greco S, Sarra-Ferraris G, et al.
miR-200c is upregulated by oxidative stress and induces endothelial cell apoptosis
and senescence via ZEB1 inhibition. Cell Death Differ 2011;18:1628–39.
[90] Zaccagnini G, Martelli F, Fasanaro P, Magenta A, Gaetano C, Di Carlo A, et al.
p66ShcA modulates tissue response to hindlimb ischemia. Circulation 2004;109:
2917–23.
[91] BaselerWA, Thapa D, Jagannathan R, Dabkowski ER, Croston TL, Hollander JM. miR-
141 as a regulator of the mitochondrial phosphate carrier (Slc25a3) in the type 1
diabetic heart. Am J Physiol Cell Physiol 2012;303:C1244–51.
[92] Pulakat L, Aroor AR, Gul R, Sowers JR. Cardiac insulin resistance and microRNA
modulators. Exp Diabetes Res 2012;2012:654904.
[93] Lin Y, Liu X, Cheng Y, Yang J, Huo Y, Zhang C. Involvement of MicroRNAs in hydro-
gen peroxide-mediated gene regulation and cellular injury response in vascular
smooth muscle cells. J Biol Chem 2009;284:7903–13.
[94] Hulsmans M, Holvoet P. The vicious circle between oxidative stress and inﬂamma-
tion in atherosclerosis. J Cell Mol Med 2010;14:70–8.[95] WeberM, BakerMB, Moore JP, Searles CD. MiR-21 is induced in endothelial cells by
shear stress and modulates apoptosis and eNOS activity. Biochem Biophys Res
Commun 2010;393:643–8.
[96] Fleissner F, Jazbutyte V, Fiedler J, Gupta SK, Yin X, Xu Q, et al. Short communication:
asymmetric dimethylarginine impairs angiogenic progenitor cell function in pa-
tients with coronary artery disease through a microRNA-21-dependent mecha-
nism. Circ Res 2010;107:138–43.
[97] Li R, Yan G, Li Q, Sun H, Hu Y, Sun J, et al. MicroRNA-145 protects cardiomyocytes
against hydrogen peroxide (H(2)O(2))-induced apoptosis through targeting the
mitochondria apoptotic pathway. PLoS ONE 2012;7:e44907.
[98] Greco S, Gaetano C, Martelli F. HypoxamiR regulation and function in ischemic car-
diovascular diseases. Antioxid Redox Signal 2014;21:1202–19.
[99] Zaccagnini G, Maimone B, Di Stefano V, Fasanaro P, Greco S, Perfetti A, et al.
Hypoxia-inducedmiR-210modulates tissue response to acute peripheral ischemia.
Antioxid Redox Signal 2014;21:1177–88.
[100] Martinet W, De Meyer GR. Autophagy in atherosclerosis: a cell survival and death
phenomenon with therapeutic potential. Circ Res 2009;104:304–17.
[101] Cuervo AM. Autophagy and aging: keeping that old broom working. Trends Genet
2008;24:604–12.
[102] Kang HT, Lee KB, Kim SY, Choi HR, Park SC. Autophagy impairment induces prema-
ture senescence in primary human ﬁbroblasts. PLoS ONE 2011;6:e23367.
[103] Menghini R, Casagrande V,Marino A,Marchetti V, Cardellini M, Stoehr R, et al. MiR-
216a: a link between endothelial dysfunction and autophagy. Cell Death Dis 2014;
5:e1029.
[104] Rogina B, Helfand SL. Sir2 mediates longevity in the ﬂy through a pathway related
to calorie restriction. Proc Natl Acad Sci U S A 2004;101:15998–6003.
[105] Bordone L, Guarente L. Calorie restriction, SIRT1 and metabolism: understanding
longevity. Nat Rev Mol Cell Biol 2005;6:298–305.
[106] Schwer B, Verdin E. Conserved metabolic regulatory functions of sirtuins. Cell
Metab 2008;7:104–12.
[107] Potente M, Dimmeler S. Emerging roles of SIRT1 in vascular endothelial homeosta-
sis. Cell Cycle 2008;7:2117–22.
[108] Dhahbi JM, Spindler SR, Atamna H, Yamakawa A, Guerrero N, Boffelli D, et al. Deep
sequencing identiﬁes circulating mouse miRNAs that are functionally implicated in
manifestations of aging and responsive to calorie restriction. Aging 2013;5:130–41.
[109] Menghini R, Casagrande V, Cardellini M, Martelli E, Terrinoni A, Amati F, et al.
MicroRNA 217 modulates endothelial cell senescence via silent information regu-
lator 1. Circulation 2009;120:1524–32.
[110] Zhang L, Huang D,Wang Q, Shen D,Wang Y, Chen B, et al. MiR-132 inhibits expres-
sion of SIRT1 and induces pro-inﬂammatory processes of vascular endothelial in-
ﬂammation through blockade of the SREBP-1c metabolic pathway. Cardiovasc
Drugs Ther 2014;28:303–11.
[111] Ponugoti B, Kim DH, Xiao Z, Smith Z, Miao J, Zang M, et al. SIRT1 deacetylates and
inhibits SREBP-1C activity in regulation of hepatic lipid metabolism. J Biol Chem
2010;285:33959–70.
[112] Kumarswamy R, Volkmann I, Beermann J, Napp LC, Jabs O, Bhayadia R, et al. Vascu-
lar importance of the miR-212/132 cluster. Eur Heart J 2014;35:3224–31.
[113] Guarani V, Deﬂorian G, Franco CA, Kruger M, Phng LK, Bentley K, et al. Acetylation-
dependent regulation of endothelial Notch signalling by the SIRT1 deacetylase. Na-
ture 2011;473:234–8.
[114] Ito T, Yagi S, Yamakuchi M. MicroRNA-34a regulation of endothelial senescence.
Biochem Biophys Res Commun 2010;398:735–40.
[115] Xu Q, Seeger FH, Castillo J, Iekushi K, Boon RA, Farcas R, et al. Micro-RNA-34a
contributes to the impaired function of bone marrow-derived mononuclear
cells from patients with cardiovascular disease. J Am Coll Cardiol 2012;59:
2107–17.
[116] Tabuchi T, Satoh M, Itoh T, Nakamura M. MicroRNA-34a regulates the longevity-
associated protein SIRT1 in coronary artery disease: effect of statins on SIRT1 and
microRNA-34a expression. Clin Sci (Lond) 2012;123:161–71.
[117] Zhu H, Yang Y, Wang Y, Li J, Schiller PW, Peng T. MicroRNA-195 promotes
palmitate-induced apoptosis in cardiomyocytes by down-regulating Sirt1.
Cardiovasc Res 2011;92:75–84.
[118] Rane S, He M, Sayed D, Vashistha H, Malhotra A, Sadoshima J, et al. Downreg-
ulation of miR-199a derepresses hypoxia-inducible factor-1alpha and Sirtuin 1
and recapitulates hypoxia preconditioning in cardiac myocytes. Circ Res 2009;
104:879–86.
[119] Abdelmohsen K, Panda A, Kang MJ, Xu J, Selimyan R, Yoon JH, et al. Senescence-
associated lncRNAs: senescence-associated long noncoding RNAs. Aging Cell
2013;12:890–900.
[120] Abdelmohsen K, Panda AC, Kang MJ, Guo R, Kim J, Grammatikakis I, et al. 7SL RNA
represses p53 translation by competing with HuR. Nucleic Acids Res 2014;42:
10099–111.
[121] Tripathi V, Shen Z, Chakraborty A, Giri S, Freier SM, Wu X, et al. Long noncoding
RNA MALAT1 controls cell cycle progression by regulating the expression of onco-
genic transcription factor B-MYB. PLoS Genet 2013;9:e1003368.
[122] Hewitt G, Jurk D, Marques FD, Correia-Melo C, Hardy T, Gackowska A, et al. Telo-
meres are favoured targets of a persistent DNA damage response in ageing and
stress-induced senescence. Nat Commun 2012;3:708.
[123] Bernardes de Jesus B, Vera E, Schneeberger K, Tejera AM, Ayuso E, Bosch F, et al.
Telomerase gene therapy in adult and old mice delays aging and increases longev-
ity without increasing cancer. EMBO Mol Med 2012;4:691–704.
[124] Redon S, Zemp I, Lingner J. A three-state model for the regulation of telomerase by
TERRA and hnRNPA1. Nucleic Acids Res 2013;41:9117–28.
[125] Wang K, Liu F, Zhou LY, Long B, Yuan SM, Wang Y, et al. The long noncoding RNA
CHRF regulates cardiac hypertrophy by targeting miR-489. Circ Res 2014;114:
1377–88.
154 S. Greco et al. / Journal of Molecular and Cellular Cardiology 83 (2015) 142–155[126] Liu H, Song G, Zhou L, Hu X, LiuM, Nie J, et al. Compared analysis of LncRNA expres-
sion proﬁling in pdk1 gene knockout mice at two time points. Cell Physiol Biochem
2013;32:1497–508.
[127] Ravingerova T, BarancikM, StrniskovaM.Mitogen-activated protein kinases: a new
therapeutic target in cardiac pathology. Mol Cell Biochem 2003;247:127–38.
[128] Wang Y, Su B, Sah VP, Brown JH, Han J, Chien KR. Cardiac hypertrophy induced by
mitogen-activated protein kinase kinase 7, a speciﬁc activator for c-Jun NH2-
terminal kinase in ventricular muscle cells. J Biol Chem 1998;273:5423–6.
[129] Podlowski S, Bramlage P, Baumann G, Morano I, Luther HP. Cardiac troponin I
sense-antisense RNA duplexes in the myocardium. J Cell Biochem 2002;85:
198–207.
[130] Annilo T, Kepp K, Laan M. Natural antisense transcript of natriuretic peptide pre-
cursor A (NPPA): structural organization and modulation of NPPA expression.
BMC Mol Biol 2009;10:81.
[131] Horsthuis T, Houweling AC, Habets PE, de Lange FJ, el Azzouzi H, Clout DE, et al. Dis-
tinct regulation of developmental and heart disease-induced atrial natriuretic fac-
tor expression by two separate distal sequences. Circ Res 2008;102:849–59.
[132] Han P, Li W, Lin CH, Yang J, Shang C, Nuernberg ST, et al. A long noncoding RNA
protects the heart from pathological hypertrophy. Nature 2014;514:102–6.
[133] Eagle KA, Nallamothu BK, Mehta RH, Granger CB, Steg PG, Van de Werf F, et al.
Trends in acute reperfusion therapy for ST-segment elevation myocardial infarc-
tion from 1999 to 2006: we are getting better but we have got a long way to go.
Eur Heart J 2008;29:609–17.
[134] Windecker S, Bax JJ, Myat A, Stone GW, Marber MS. Future treatment strategies in
ST-segment elevation myocardial infarction. Lancet 2013;382:644–57.
[135] White HD, Chew DP. Acute myocardial infarction. Lancet 2008;372:570–84.
[136] Liu Y, Li G, Lu H, Li W, Li X, Liu H, et al. Expression proﬁling and ontology analysis of
long noncoding RNAs in post-ischemic heart and their implied roles in ischemia/
reperfusion injury. Gene 2014;543:15–21.
[137] Zangrando J, Zhang L, Vausort M, Maskali F, Marie PY, Wagner DR, et al. Identiﬁca-
tion of candidate long non-coding RNAs in response to myocardial infarction. BMC
Genomics 2014;15:460.
[138] Broadbent HM, Peden JF, Lorkowski S, Goel A, Ongen H, Green F, et al. Susceptibility
to coronary artery disease and diabetes is encoded by distinct, tightly linked SNPs
in the ANRIL locus on chromosome 9p. Hum Mol Genet 2008;17:806–14.
[139] Cugino D, Gianfagna F, Santimone I, de Gaetano G, Donati MB, Iacoviello L, et al.
Type 2 diabetes and polymorphisms on chromosome 9p21: a meta-analysis. Nutr
Metab Cardiovasc Dis 2012;22:619–25.
[140] Jeck WR, Siebold AP, Sharpless NE. Review: a meta-analysis of GWAS and age-
associated diseases. Aging Cell 2012;11:727–31.
[141] Holdt LM, Teupser D. From genotype to phenotype in human atherosclerosis—recent
ﬁndings. Curr Opin Lipidol 2013;24:410–8.
[142] Holdt LM, Teupser D. Recent studies of the human chromosome 9p21 locus, which
is associated with atherosclerosis in human populations. Arterioscler Thromb Vasc
Biol 2012;32:196–206.
[143] Holdt LM, Beutner F, Scholz M, Gielen S, Gabel G, Bergert H, et al. ANRIL expression
is associated with atherosclerosis risk at chromosome 9p21. Arterioscler Thromb
Vasc Biol 2010;30:620–7.
[144] Holdt LM, Hoffmann S, Sass K, Langenberger D, Scholz M, Krohn K, et al. Alu ele-
ments in ANRIL non-coding RNA at chromosome 9p21 modulate atherogenic cell
functions through trans-regulation of gene networks. PLoS Genet 2013;9:
e1003588.
[145] Cortez MA, Calin GA. MicroRNA identiﬁcation in plasma and serum: a new tool to
diagnose and monitor diseases. Expert Opin Biol Ther 2009;9:703–11.
[146] Huang X, Yuan T, Tschannen M, Sun Z, Jacob H, Du M, et al. Characterization of
human plasma-derived exosomal RNAs by deep sequencing. BMC Genomics
2013;14:319.
[147] Chen X, Ba Y, Ma L, Cai X, Yin Y, Wang K, et al. Characterization of microRNAs in
serum: a novel class of biomarkers for diagnosis of cancer and other diseases.
Cell Res 2008;18:997–1006.
[148] Hunter MP, Ismail N, Zhang X, Aguda BD, Lee EJ, Yu L, et al. Detection of microRNA
expression in human peripheral blood microvesicles. PLoS ONE 2008;3:e3694.
[149] Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL,
et al. Circulating microRNAs as stable blood-based markers for cancer detection.
Proc Natl Acad Sci U S A 2008;105:10513–8.
[150] Gilad S, Meiri E, Yogev Y, Benjamin S, Lebanony D, Yerushalmi N, et al. Serum
microRNAs are promising novel biomarkers. PLoS ONE 2008;3:e3148.
[151] Weber JA, Baxter DH, Zhang S, Huang DY, Huang KH, Lee MJ, et al. The microRNA
spectrum in 12 body ﬂuids. Clin Chem 2010;56:1733–41.
[152] van Empel VP, De Windt LJ, da Costa Martins PA. Circulating miRNAs: reﬂecting or
affecting cardiovascular disease? Curr Hypertens Rep 2012;14:498–509.
[153] Gupta SK, Bang C, Thum T. Circulating microRNAs as biomarkers and potential
paracrine mediators of cardiovascular disease. Circ Cardiovasc Genet 2010;3:
484–8.
[154] Xu J, Zhao J, Evan G, Xiao C, Cheng Y, Xiao J. Circulating microRNAs: novel bio-
markers for cardiovascular diseases. J Mol Med 2012;90:865–75.
[155] da Silva AM Gomes, Silbiger VN. miRNAs as biomarkers of atrial ﬁbrillation. Bio-
markers 2014:1–6.
[156] Zampetaki A, Willeit P, Drozdov I, Kiechl S, Mayr M. Proﬁling of circulating
microRNAs: from single biomarkers to re-wired networks. Cardiovasc Res 2012;
93:555–62.
[157] Fasanaro P, D'Alessandra Y, Magenta A, Pompilio G, Capogrossi MC. MicroRNAs:
promising biomarkers and therapeutic targets of acute myocardial ischemia. Curr
Vasc Pharmacol 2013.
[158] Di Stefano V, Zaccagnini G, Capogrossi MC, Martelli F. microRNAs as peripheral
blood biomarkers of cardiovascular disease. Vasc Pharmacol 2011;55:111–8.[159] D'Alessandra Y, Devanna P, Limana F, Straino S, Di Carlo A, Brambilla PG, et al. Cir-
culatingmicroRNAs are new and sensitive biomarkers of myocardial infarction. Eur
Heart J 2010;31:2765–73.
[160] Chen X, Liang H, Zhang J, Zen K, Zhang CY. Secreted microRNAs: a new form of in-
tercellular communication. Trends Cell Biol 2012;22:125–32.
[161] Loyer X, Vion AC, Tedgui A, Boulanger CM. Microvesicles as cell–cell messengers in
cardiovascular diseases. Circ Res 2014;114:345–53.
[162] Ren J, Zhang J, Xu N, Han G, Geng Q, Song J, et al. Signature of circulatingmicroRNAs
as potential biomarkers in vulnerable coronary artery disease. PLoS ONE 2013;8:
e80738.
[163] Wang GK, Zhu JQ, Zhang JT, Li Q, Li Y, He J, et al. Circulating microRNA: a novel po-
tential biomarker for early diagnosis of acute myocardial infarction in humans. Eur
Heart J 2010;31:659–66.
[164] Sayed AS, Xia K, Yang TL, Peng J. Circulating microRNAs: a potential role in diagno-
sis and prognosis of acute myocardial infarction. Dis Markers 2013;35:561–6.
[165] Cui J, Zhao N. Consideration in selection of the control group in diagnostic tests. Int J
Biol Sci 2012;8:1418–9.
[166] Olivieri F, Antonicelli R, Lorenzi M, D'Alessandra Y, Lazzarini R, Santini G, et al. Di-
agnostic potential of circulating miR-499-5p in elderly patients with acute non ST-
elevation myocardial infarction. Int J Cardiol 2013;167:531–6.
[167] Olivieri F, Antonicelli R, Spazzafumo L, Santini G, Rippo MR, Galeazzi R, et al.
Admission levels of circulating miR-499-5p and risk of death in elderly pa-
tients after acute non-ST elevation myocardial infarction. Int J Cardiol 2014;
172:e276–8.
[168] Thum T, Mayr M. Review focus on the role of microRNA in cardiovascular biology
and disease. Cardiovasc Res 2012;93:543–4.
[169] Fichtlscherer S, Zeiher AM, Dimmeler S. Circulating microRNAs: biomarkers or medi-
ators of cardiovascular diseases? Arterioscler Thromb Vasc Biol 2011;31:2383–90.
[170] D'Alessandra Y, Carena MC, Spazzafumo L, Martinelli F, Bassetti B, Devanna P, et al.
Diagnostic potential of plasmatic MicroRNA signatures in stable and unstable angi-
na. PLoS ONE 2013;8:e80345.
[171] HoekstraM, van der Lans CA, Halvorsen B, Gullestad L, Kuiper J, Aukrust P, et al. The
peripheral blood mononuclear cell microRNA signature of coronary artery disease.
Biochem Biophys Res Commun 2010;394:792–7.
[172] Tijsen AJ, Creemers EE, Moerland PD, de Windt LJ, van der Wal AC, Kok WE, et al.
MiR423-5p as a circulating biomarker for heart failure. Circ Res 2010;106:1035–9.
[173] Corsten MF, Dennert R, Jochems S, Kuznetsova T, Devaux Y, Hofstra L, et al. Circu-
latingmicroRNA-208b and microRNA-499 reﬂect myocardial damage in cardiovas-
cular disease. Circ Cardiovasc Genet 2010;3:499–506.
[174] Voellenkle C, van Rooij J, Cappuzzello C, Greco S, Arcelli D, Di Vito L, et al. MicroRNA
signatures in peripheral blood mononuclear cells of chronic heart failure patients.
Physiol Genomics 2010;42:420–6.
[175] Caporali A, Meloni M, Vollenkle C, Bonci D, Sala-Newby GB, Addis R, et al. Deregu-
lation of microRNA-503 contributes to diabetes mellitus-induced impairment of
endothelial function and reparative angiogenesis after limb ischemia. Circulation
2011;123:282–91.
[176] Dhahbi JM, Kim HJ, Mote PL, Beaver RJ, Spindler SR. Temporal linkage between the
phenotypic and genomic responses to caloric restriction. Proc Natl Acad Sci U S A
2004;101:5524–9.
[177] Pollack M, Phaneuf S, Dirks A, Leeuwenburgh C. The role of apoptosis in the normal
aging brain, skeletal muscle, and heart. Ann N Y Acad Sci 2002;959:93–107.
[178] Higami Y, Shimokawa I. Apoptosis in the aging process. Cell Tissue Res 2000;301:
125–32.
[179] Vausort M, Wagner DR, Devaux Y. Long noncoding RNAs in patients with acute
myocardial infarction. Circ Res 2014;115:668–77.
[180] Li D, Chen G, Yang J, Fan X, Gong Y, Xu G, et al. Transcriptome analysis reveals dis-
tinct patterns of long noncoding RNAs in heart and plasma of mice with heart fail-
ure. PLoS ONE 2013;8:e77938.
[181] Kumarswamy R, Bauters C, Volkmann I, Maury F, Fetisch J, Holzmann A, et al. Cir-
culating long noncoding RNA, LIPCAR, predicts survival in patients with heart fail-
ure. Circ Res 2014;114:1569–75.
[182] He X, He L, Hannon GJ. The guardian's little helper: microRNAs in the p53 tumor
suppressor network. Cancer Res 2007;67:11099–101.
[183] Janssen HL, Reesink HW, Lawitz EJ, Zeuzem S, Rodriguez-Torres M, Patel K, et al.
Treatment of HCV infection by targeting microRNA. N Engl J Med 2013;368:1685–94.
[184] Wheeler TM, Leger AJ, Pandey SK, MacLeod AR, Nakamori M, Cheng SH, et al.
Targeting nuclear RNA for in vivo correction of myotonic dystrophy. Nature
2012;488:111–5.
[185] Takahashi H, Carninci P. Widespread genome transcription: new possibilities for
RNA therapies. Biochem Biophys Res Commun 2014;452:294–301.
[186] Kaufmann KB, Buning H, Galy A, Schambach A, Grez M. Gene therapy on the move.
EMBO Mol Med 2013;5:1642–61.
[187] Verma IM, Weitzman MD. Gene therapy: twenty-ﬁrst century medicine. Annu Rev
Biochem 2005;74:711–38.
[188] Greco S, Fasanaro P, Castelvecchio S, D'Alessandra Y, Arcelli D, Di Donato M, et al.
MicroRNA dysregulation in diabetic ischemic heart failure patients. Diabetes
2012;61:1633–41.
[189] Lee JH, Gao C, Peng G, Greer C, Ren S, Wang Y, et al. Analysis of transcriptome com-
plexity through RNA sequencing in normal and failing murine hearts. Circ Res
2011;109:1332–41.
[190] Ritter O, Haase H, Schulte HD, Lange PE, Morano I. Remodeling of the
hypertrophied human myocardium by cardiac bHLH transcription factors. J Cell
Biochem 1999;74:551–61.
[191] Ai J, Zhang R, Li Y, Pu J, Lu Y, Jiao J, et al. Circulating microRNA-1 as a potential novel
biomarker for acute myocardial infarction. Biochem Biophys Res Commun 2010;
391:73–7.
155S. Greco et al. / Journal of Molecular and Cellular Cardiology 83 (2015) 142–155[192] Cheng Y, Tan N, Yang J, Liu X, Cao X, He P, et al. A translational study of circulating
cell-free microRNA-1 in acute myocardial infarction. Clin Sci (Lond) 2010;119:
87–95.
[193] Gidlof O, Andersson P, van der Pals J, Gotberg M, Erlinge D. Cardiospeciﬁc
microRNA plasma levels correlate with troponin and cardiac function in pa-
tients with ST elevation myocardial infarction, are selectively dependent on
renal elimination, and can be detected in urine samples. Cardiology 2011;
118:217–26.
[194] Li YQ, Zhang MF, Wen HY, Hu CL, Liu R, Wei HY, et al. Comparing the diagnostic
values of circulatingmicroRNAs and cardiac troponin T in patients with acutemyo-
cardial infarction. Clinics (Sao Paulo) 2013;68:75–80.
[195] Wang R, Li N, Zhang Y, Ran Y, Pu J. Circulating microRNAs are promising novel bio-
markers of acute myocardial infarction. Intern Med J 2011;50:1789–95.
[196] Long G, Wang F, Duan Q, Yang S, Chen F, Gong W, et al. Circulating miR-30a, miR-
195 and let-7b associated with acute myocardial infarction. PLoS ONE 2012;7:
e50926.
[197] Long G, Wang F, Duan Q, Chen F, Yang S, Gong W, et al. Human circulating
microRNA-1 and microRNA-126 as potential novel indicators for acute myocardial
infarction. Int J Biol Sci 2012;8:811–8.
[198] Fichtlscherer S, De Rosa S, Fox H, Schwietz T, Fischer A, Liebetrau C, et al. Circulating
microRNAs in patients with coronary artery disease. Circ Res 2010;107:677–84.
[199] Hullinger TG, Montgomery RL, Seto AG, Dickinson BA, Semus HM, Lynch JM, et al.
Inhibition of miR-15 protects against cardiac ischemic injury. Circ Res 2012;110:
71–81.
[200] Chen J, Huang ZP, Seok HY, Ding J, Kataoka M, Zhang Z, et al. mir-17-92 cluster is
required for and sufﬁcient to induce cardiomyocyte proliferation in postnatal and
adult hearts. Circ Res 2013;112:1557–66.
[201] Fiedler J, Jazbutyte V, Kirchmaier BC, Gupta SK, Lorenzen J, Hartmann D, et al.
MicroRNA-24 regulates vascularity after myocardial infarction. Circulation 2011;
124:720–30.
[202] van Rooij E, Sutherland LB, Thatcher JE, DiMaio JM, Naseem RH, Marshall WS, et al.
Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in
cardiac ﬁbrosis. Proc Natl Acad Sci U S A 2008;105:13027–32.
[203] Ren XP,Wu J,Wang X, Sartor MA, Qian J, Jones K, et al. MicroRNA-320 is involved in
the regulation of cardiac ischemia/reperfusion injury by targeting heat-shock pro-
tein 20. Circulation 2009;119:2357–66.[204] Eulalio A, Mano M, Dal Ferro M, Zentilin L, Sinagra G, Zacchigna S, et al. Functional
screening identiﬁes miRNAs inducing cardiac regeneration. Nature 2012;492:
376–81.
[205] van Rooij E, Sutherland LB, Qi X, Richardson JA, Hill J, Olson EN. Control of stress-
dependent cardiac growth and gene expression by a microRNA. Science 2007;
316:575–9.
[206] Callis TE, Pandya K, Seok HY, Tang RH, Tatsuguchi M, Huang ZP, et al. MicroRNA-
208a is a regulator of cardiac hypertrophy and conduction in mice. J Clin Invest
2009;119:2772–86.
[207] Montgomery RL, Hullinger TG, Semus HM, Dickinson BA, Seto AG, Lynch JM, et al.
Therapeutic inhibition of miR-208a improves cardiac function and survival during
heart failure. Circulation 2011;124:1537–47.
[208] Ucar A, Gupta SK, Fiedler J, Erikci E, Kardasinski M, Batkai S, et al. The miRNA-212/
132 family regulates both cardiac hypertrophy and cardiomyocyte autophagy. Nat
Commun 2012;3:1078.
[209] Care A, Catalucci D, Felicetti F, Bonci D, Addario A, Gallo P, et al. MicroRNA-133 con-
trols cardiac hypertrophy. Nat Med 2007;13:613–8.
[210] Pan Z, Sun X, Shan H, Wang N, Wang J, Ren J, et al. MicroRNA-101 inhibited
postinfarct cardiac ﬁbrosis and improved left ventricular compliance via the FBJ os-
teosarcoma oncogene/transforming growth factor-beta1 pathway. Circulation
2012;126:840–50.
[211] Li RC, Tao J, Guo YB,WuHD, Liu RF, Bai Y, et al. In vivo suppression of microRNA-24
prevents the transition toward decompensated hypertrophy in aortic-constricted
mice. Circ Res 2013;112:601–5.
[212] Huang ZP, Chen J, Seok HY, Zhang Z, Kataoka M, Hu X, et al. MicroRNA-22 regulates
cardiac hypertrophy and remodeling in response to stress. Circ Res 2013;112:
1234–43.
[213] da Costa Martins PA, Salic K, Gladka MM, Armand AS, Leptidis S, el Azzouzi H, et al.
MicroRNA-199b targets the nuclear kinase Dyrk1a in an auto-ampliﬁcation loop
promoting calcineurin/NFAT signalling. Nat Cell Biol 2010;12:1220–7.
[214] Ganesan J, Ramanujam D, Sassi Y, Ahles A, Jentzsch C, Werfel S, et al. MiR-378 con-
trols cardiac hypertrophy by combined repression of mitogen-activated protein ki-
nase pathway factors. Circulation 2013;127:2097–106.
